Trends in Immunotherapy

Article

Modified Wumei Pills: Network Pharmacology and Bioinformatics in Colon Cancer Treatment

Downloads

https://doi.org/10.54963/ti.v9i1.989
Liu, S., Liu, G., Li, C., & Zhang, R. (2025). Modified Wumei Pills: Network Pharmacology and Bioinformatics in Colon Cancer Treatment. Trends in Immunotherapy, 9(1), 45–67. https://doi.org/10.54963/ti.v9i1.989
Volume 9 Issue 1 (2025)
Copyright (c) 2025 Shichao Liu, Guancheng Liu, Chen Li, Rui Zhang
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

This study investigates the therapeutic mechanisms of modified Wumei pills in colon cancer treatment, utilizing network pharmacology and bioinformatics to uncover the active ingredients and their corresponding targets that intersect with colon cancer-related genes.We identified the active components of Wumei pills using the TCMSP database and predicted their targets with Swiss Target Prediction. Disease-related targets were identified through GeneCards and Disgenet. Network analysis, GO, KEGG, and PPI network construction were performed. Immunohistochemical assessments validated gene expression patterns, and ROC curve and Cox regression analyses evaluated the prognostic significance and patient prognosis correlation.The study revealed 112 common targets associated with colon cancer, with six key genes (ADRA2B, CXCR3, CYP19A1, NR1H2, PAPPA, PGR) prioritized. Functional enrichment analyses indicated significant associations with biological processes and pathways related to colon cancer. Immunohistochemical assessments confirmed the expression patterns of these genes within colon cancer tissues. ROC curve analysis highlighted the prognostic significance of the PGR gene, while molecular docking and molecular dynamics simulation studies demonstrated robust binding affinity of active components to their targets, particularly Diop with CXCR3.The research provides a scientific framework for the application of modified Wumei pills in colon cancer management, identifying potential key genes and pathways. The findings suggest that these pills could influence tumor growth and the immune microenvironment, offering novel insights for targeted therapy and immunotherapy in colon cancer treatment.

Keywords:

ModiFied Wumei Pill; Colon Cancer; Network Pharmacology; Bioinformatics; Molecular Docking

References

  1. Huang, J., Zheng, Y., Ma, J., et al. Exploration of the potential mechanisms of Wumei pill for the treatment of Ulcerative Colitis by network pharmacology. Gastroenterol. Res. Pract. 2021, 2021, 4227668. DOI: https://doi.org/10.1155/2021/4227668
  2. Yeh, M.H., Chiu, H.P., Wu, M.C., et al. Integrated Chinese herbal medicine and western medicine on the survival in patients with colorectal cancer: A retrospective study of medical records. Evid.‐Based Complement. Altern. Med. 2020, 2020, 4561040. DOI: https://doi.org/10.1155/2020/4561040
  3. Lu, D.X., Liu, F., Wu, H., et al. Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-kappaB pathway and microbiota regulation. World J. Gastroenterol. 2022, 28, 4574. DOI: https://doi.org/10.3748/wjg.v28.i32.4574
  4. Wang, J., Ding, K., Wang, Y., et al. Wumei pill ameliorates AOM/DSS-induced colitis-associated colon cancer through inhibition of inflammation and oxidative stress by regulating S-adenosylhomocysteine hydrolase- (AHCY-) mediated Hedgehog signaling in mice. Oxidative Med. Cell. Longev. 2022, 2022, 4061713. DOI: https://doi.org/10.1155/2022/4061713
  5. Sun, Q., He, M., Zhang, M., et al. Traditional Chinese medicine and colorectal cancer: Implications for drug discovery. Front. Pharmacol. 2021, 12, 685002. DOI: https://doi.org/10.3389/fphar.2021.685002
  6. Zhuang, Z., Wen, J., Zhang, L., et al. Can network pharmacology identify the anti-virus and anti- inflammatory activities of Shuanghuanglian oral liquid used in Chinese medicine for respiratory tract infection? Eur. J. Integr. Med. 2020, 37, 101139. DOI: https://doi.org/10.1016/j.eujim.2020.101139
  7. Zou, Y., Wang, S., Zhang, H., et al. The triangular relationship between traditional Chinese medicines, intestinal flora, and colorectal cancer. Med. Res. Rev. 2024, 44, 539–567. DOI: https://doi.org/10.1002/med.21989
  8. Lu, Z.H., Ding, Y., Wang, Y.J., et al. Early administration of Wumei Wan inhibit myeloid-derived suppressor cells via PI3K/Akt pathway and amino acids metabolism to prevent colitis-associated colorectal cancer. J. Ethnopharmacol. 2024, 333, 118260. DOI: https://doi.org/10.1016/j.jep.2024.118260
  9. Zhang, M., Lu, B. To investigate the molecular mechanism of Wugedan pill in improving insulin resistance based on network pharmacology. MEDS Chin. Med. 2022, 4, 31–39. DOI: https://doi.org/10.23977/medcm.2022.040305
  10. Yin, H., Liu, W., Ji, X., et al. Study on the mechanism of Wumei San in treating piglet diarrhea using network pharmacology and molecular docking. Front. Vet. Sci. 2023, 10, 1138684. DOI: https://doi.org/10.3389/fvets.2023.1138684
  11. Shao, S.Y., Li, Q. Research progress in the treatment of colorectal cancer in classical prescriptions. TMR Cancer 2019, 2, 200–205. DOI: https://doi.org/10.12032/TMRC201800056
  12. Fan, Y.H., Li, T.D., Gong, R., et al. Mechanism of Wumei pill in the treatment of non-erosive reflux disease from the perspective of network pharmacology and molecular docking. Asian Toxicol. Res. 2021, 3, 15. DOI: https://doi.org/10.53388/atr2021110101.
  13. Fu, Y., Gao, C., Sun, X., et al. Study on the mechanism of action of Wu Mei Pill in inhibiting rheumatoid arthritis through TLR4-NF-kappaB pathway. J. Orthop. Surg. Res. 2024, 19, 65. DOI: https://doi.org/10.1186/s13018-024-04551-z.
  14. Guan, Z., Zhao, Q., Huang, Q., et al. Modified Renshen Wumei decoction alleviates intestinal barrier destruction in rats with diarrhea. J. Microbiol. Biotechnol. 2021, 31, 1295. DOI: https://doi.org/10.4014/jmb.2106.06037.
  15. Lin, X., Yang, X., Yang, Y., et al. Research progress of traditional Chinese medicine as sensitizer in reversing chemoresistance of colorectal cancer. Front. Oncol. 2023, 13, 1132141. DOI: https://doi.org/10.3389/fonc.2023.1132141.
  16. Lyu, M., Wang, Y., Chen, Q., et al., 2022. Molecular mechanism underlying effects of wumeiwan on steroid-dependent asthma: A network pharmacology, molecular docking, and experimental verification study. Drug Des. Dev. Ther. 2022, 16, 909–929. DOI: https://doi.org/10.2147/DDDT.S349950.
  17. Morgan, E., Arnold, M., Gini, A., et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 2023, 72, 338–344. DOI: https://doi.org/10.1136/gutjnl-2022-327736.
  18. Sun, C., Xiao, K., He, Y., et al., 2024. Common mechanisms of Wumei pills in treating ulcerative colitis and type 2 diabetes: Exploring an integrative approach through network pharmacology. Med. (Baltim.) 2024, 103, e37094. DOI: https://doi.org/10.1097/MD.0000000000037094
  19. Wan, Y., Xu, L., Liu, Z., et al., 2019. Utilising network pharmacology to explore the underlying mechanism of Wumei Pill in treating pancreatic neoplasms. BMC Complement. Altern. Med. 2019, 19, 158. DOI: https://doi.org/10.1186/s12906-019-2580-y
  20. Wei, X., Leng, X., Li, G., et al., 2023. Advances in research on the effectiveness and mechanism of Traditional Chinese Medicine formulas for colitis-associated colorectal cancer. Front. Pharmacol. 2023, 14, 1120672. DOI: https://doi.org/10.3389/fphar.2023.1120672
  21. Cheng, J., Zheng, J., Liu, Y., et al., 2019. Efficacy of traditional Chinese medication Tangminling pill in Chinese patients with type 2 diabetes. Biosci. Rep. 2019, 39, BSR20181729. DOI: https://doi.org/10.1042/BSR20181729
  22. Lee, K., Choi, Y.J., Lim, H.I., et al. Network pharmacology study to explore the multiple molecular mechanism of SH003 in the treatment of non-small cell lung cancer. BMC Complement. Med. Ther. 2024, 24, 70. DOI: https://doi.org/10.1186/s12906-024-04347-y
  23. Ma, T., Ji, P., Wu, F.L., et al., 2024. Research on the mechanism of Guanyu Zhixie Granule in intervening gastric ulcers in rats based on network pharmacology and multi-omics. Front. Vet. Sci. 2024, 11, 1390473. DOI: https://doi.org/10.3389/fvets.2024.1390473
  24. Ni, Z., Ma, Z., Qiao, X., et al. Prediction and analysis of components and functions of Ixeris chinensis based on network pharmacology and molecular docking. Front. Med. 2024, 11, 1360966. DOI: https://doi.org/10.3389/fmed.2024.1360966
  25. Wang, T., Liang, L., Zhao, C., et al., 2021. Elucidating direct kinase targets of compound Danshen dropping pills employing archived data and prediction models. Sci. Rep. 2021, 11, 9541. DOI: https://doi.org/10.1038/s41598-021-89035-4
  26. Yuan, Y., Hu, H., Sun, Z., et al., 2024. Combining metagenomics, network pharmacology and RNA-seq strategies to reveal the therapeutic effects and mechanisms of Qingchang Wenzhong decoction on inflammatory bowel disease in mice. Drug Des. Dev. Ther. 2024, 18, 4273–4289. DOI: https://doi.org/10.2147/DDDT.S473688
  27. Chen, X., Shi, J., Lai, Y., et al. Systematic analysis of randomised controlled trials of Chinese herb medicine for non-alcoholic steatohepatitis (NASH): implications for future drug development and trial design. Chin. Med. 2023, 18, 58. DOI: https://doi.org/10.1186/s13020-023-00761-5
  28. Jiang, N., Li, H., Sun, Y., et al. Network pharmacology and pharmacological evaluation reveals the mechanism of the Sanguisorba officinalis in suppressing hepatocellular carcinoma. Front. Pharmacol. 2021, 12, 618522. DOI: https://doi.org/10.3389/fphar.2021.618522